Novo Holdings co-leads Hemabs USD55m Series A Novo Holdings co-leads Hemabs USD55m Series A Submitted 22|07|2021 - 9:26am Novo Holdings, an international life science investor, has co-led, alongside HealthCap and RA Capital Management, a USD55 million Series A financing in Hemab, a biotech company developing next generation therapeutics for serious underserved bleeding and thrombosis disorders. The Company was created in 2020 by Novo Seeds, the early stage investment and company creation team of Novo Holdings, which worked closely with the founders to develop a commercially attractive business plan to maximise the potential of Hemabs promising technology platform. Benny Sorensen, MD, PhD, who served on Hemabs Board of Directors, has been appointed Chief Executive Officer and will be based in the US. Dr Sorensen brings a wealth of patient-centred RD experience in many therapeutic areas including thrombosis and hemostasis. Until recently, Dr Sorensen served as Head of Clinical Development at Codiak BioSciences and has moved to be on its Scientific Advisory Board.